Can drug repurposing strategies be the solution to the COVID-19 crisis?
Expert Opin Drug Discov
; 16(6): 605-612, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: covidwho-990443
ABSTRACT
Introduction:
The COVID-19 pandemic resulted in disastrous human and economic costs, mainly due to the initial lack of specific treatments. Complementary to immunotherapies, drug repurposing is possibly the best option to arrive at COVID-19 treatments in the short term.Areas covered Repurposing prospects undergoing clinical trials or with some level of evidence emerging from clinical studies are overviewed. The authors discuss some possible intellectual property and commercial barriers to drug repurposing, and strategies to facilitate equitable access to incoming therapeutic solutions, highlighting the importance of collaborative drug discovery models. Based on a critical analysis of the available literature about in silico screens against SARS-CoV-2 main protease, the authors illustrate how frequently overconfident conclusions are being drawn in COVID-19-related literature.Expert opinion Most of the current clinical trials on potential COVID-19 treatments are, in fact, drug repurposing examples. In October 2020, the FDA approved a repurposed antiviral, remdesivir, as the first treatment for COVID-19. Considering the high expectations invested in approaching therapeutic solutions, the scientific community must be careful not to raise unrealistic expectations. Today more than ever, the conclusions drawn in scientific reports have to be fully supported by the level of evidence, avoiding any sort of unfounded speculation.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Adenosina Monofosfato
/
Alanina
/
Reposicionamiento de Medicamentos
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudios diagnósticos
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Límite:
Humanos
Idioma:
Inglés
Revista:
Expert Opin Drug Discov
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
17460441.2021.1863943
Similares
MEDLINE
...
LILACS
LIS